CHMP Fast-Tracks BMS' Empliciti Nod
This article was originally published in Scrip
Bristol-Myers Squibb and AbbVie's novel treatment for multiple myeloma, Empliciti (elotuzumab), is set for EU approval after a speedy positive opinion from the CHMP. The development follows an earlier than expected approval at the US FDA last November for the same indication.
You may also be interested in...
The market opportunity in the EU for Alexion’s Soliris has increased following European Commission approval of the additional indication, NMOSD. The EU indications for Bristol-Myers Squibb’s Empliciti have been extended to include use with pomalidomide and dexamethasone in a triplet combination for relapsed and refractory multiple myeloma.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.